Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP673353.RASoItGcCF3AMQS1o0-opICSuYHVHrvq9sJ6rS91ZI6KQ130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673353.RASoItGcCF3AMQS1o0-opICSuYHVHrvq9sJ6rS91ZI6KQ130_provenance.
• NP673440.RASFdh7TOEFDAaNF4JX4-gumceR4G6ETkFyj0ZADfV8rc130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673440.RASFdh7TOEFDAaNF4JX4-gumceR4G6ETkFyj0ZADfV8rc130_provenance.
• NP760872.RAAbBNU2vj_PHqPP8M7e6DEyZ8YwRH57DRnkpyR5aljlY130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP760872.RAAbBNU2vj_PHqPP8M7e6DEyZ8YwRH57DRnkpyR5aljlY130_provenance.
• NP760874.RADD0ppk0zXHxkCCUhGvlqZKYfMrYQD0dulW-l5Zd_pfQ130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP760874.RADD0ppk0zXHxkCCUhGvlqZKYfMrYQD0dulW-l5Zd_pfQ130_provenance.
• NP673523.RANEb5FXMllv7A07391PJYQ7Sjmf8SDDhd-3B-GsWMJ6U130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673523.RANEb5FXMllv7A07391PJYQ7Sjmf8SDDhd-3B-GsWMJ6U130_provenance.
• NP760871.RANrzbFd-tG3Q0tHekiDDD8n5wgyjNhFfRDHHVBBN3SYg130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP760871.RANrzbFd-tG3Q0tHekiDDD8n5wgyjNhFfRDHHVBBN3SYg130_provenance.
• NP673187.RAy4UD_si5vIqyVfY6--E7Dw2ZyGaDEEieH06fbmREiak130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673187.RAy4UD_si5vIqyVfY6--E7Dw2ZyGaDEEieH06fbmREiak130_provenance.
• NP760870.RA0a4dPi6SomLvBgP4AQJ-wnGHFB-0nVq9ou4sxDkWBr4130_assertion description "[Nonclassic adrenal hyperplasia should be excluded in all women presenting with hirsutism, with use of a basal follicular phase 17-hydroxyprogesterone level, regardless of the presence of polycystic ovaries or metabolic dysfunction; however, women with nonclassic adrenal hyperplasia have a higher prevalence of normal ovulation and lower likelihood of having an LH/FSH ratio >2 or polycystic ovaries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP760870.RA0a4dPi6SomLvBgP4AQJ-wnGHFB-0nVq9ou4sxDkWBr4130_provenance.